Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | MAOA | P21397 | 4/20 | 0.67 |
| ▸ | MAOB | P27338 | 4/20 | 0.67 |
| ▸ | APP | P05067 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | BACE1 | P56817 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | CDK4 | P11802 | 1/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.51 |
| ▸ | CCND1 | P24385 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL865349 | 0.94 | RAB9A (0.71) | RAB9AMAOAMAOBALDH1A1KDM4E | |
| SCHEMBL158270 | 0.92 | RAB9A (0.68) | RAB9AMAOAMAOBALDH1A1KDM4E | |
| SCHEMBL23223734 | 0.90 | RAB9A (0.69) | RAB9AMAOAMAOBAPPALDH1A1 | |
| SCHEMBL11614936 | 0.90 | RAB9A (0.69) | RAB9AMAOAMAOBAPPALDH1A1 | |
| SCHEMBL1300116 | 0.90 | RAB9A (0.65) | RAB9AMAOAMAOBALDH1A1KDM4E | |
| SCHEMBL6187222 | 0.87 | RAB9A (0.62) | RAB9AMAOAMAOBALDH1A1KDM4E | |
| SCHEMBL1222314 | 0.87 | RAB9A (0.62) | RAB9AMAOAMAOBALDH1A1KDM4E | |
| SCHEMBL1164139 | 0.87 | MAOB (0.74) | RAB9AMAOAMAOBALDH1A1KDM4E | |
| SCHEMBL1554529 | 0.86 | RAB9A (0.60) | RAB9AMAOAMAOBALDH1A1KDM4E | |
| SCHEMBL8806830 | 0.85 | RAB9A (0.60) | RAB9AMAOAMAOBALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210002649-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2021-01-07 | — | — | US | claimed |
| EP-3506911-A1 | COMPOSITIONS AND METHODS FOR TREATNG CANCER | Beth Israel Deaconess Medical Center, Inc. (US) | 2019-07-10 | — | — | EP | claimed |
| WO-2018044875-A1 | COMPOSITIONS AND METHODS FOR TREATNG CANCER | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2018-03-08 | — | — | WO | claimed |
| US-4380629-A | Styryl-like compounds showing a color-developing and bleaching behavior with improved stability and prolonged lifetime | MATSUSHITA ELECTRIC INDUSTRIAL COMPANY, LIMITED (JP) | 1983-04-19 | — | — | US | claimed |
| US-20210002649-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2021-01-07 | — | — | US | disclosed |
| US-10357477-B2 | Anticancer compounds | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2019-07-23 | — | — | US | disclosed |
| EP-3506911-A1 | COMPOSITIONS AND METHODS FOR TREATNG CANCER | Beth Israel Deaconess Medical Center, Inc. (US) | 2019-07-10 | — | — | EP | disclosed |
| EP-2505576-B1 | CYCLIC COMPOUND, PROCESS FOR PRODUCTION THEREOF, RADIATION-SENSITIVE COMPOSITION, AND RESIST PATTERN FORMATION METHOD | MITSUBISHI GAS CHEMICAL CO (JP) | 2019-04-24 | — | — | EP | disclosed |
| US-20180071258-A1 | ANTICANCER COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2018-03-15 | — | — | US | disclosed |
| WO-2018044875-A1 | COMPOSITIONS AND METHODS FOR TREATNG CANCER | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2018-03-08 | — | — | WO | disclosed |
| US-9856252-B2 | 2-(hetero)aryl-benzimidazole and imidazopyridine derivatives as inhibitors of asparagime emethyl transferase | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2018-01-02 | — | — | US | disclosed |
| EP-2958898-B1 | 2-(HETERO)ARYL-BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF ASPARAGIME EMETHYL TRANSFERASE | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2017-07-19 | — | — | EP | disclosed |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20060135613-A1 | Carboxamides derivatives | BAYER HEALTHCARE AG (DE) | 2006-06-22 | — | — | US | disclosed |
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| EP-1556349-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | Astrazeneca AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| EP-1515942-A1 | CARBOXAMIDES DERIVATIVES | Bayer HealthCare AG (DE) | 2005-03-23 | — | — | EP | disclosed |
| WO-2004033427-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2004-04-22 | — | — | WO | disclosed |
| WO-2003106403-A1 | CARBOXAMIDES DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2003-12-24 | — | — | WO | disclosed |
| US-5399575-A | Antiallergens | BOEHRINGER MANNHEIM GMBH (DE) | 1995-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071258-A1 | ANTICANCER COMPOUNDS | RB1, MCL1, TP53 | RAB9A 375/4885MAOA 3068/4885MAOB 2096/4885 |
| US-20060135613-A1 | Carboxamides derivatives | BPHL, HRH2, HRH4 | RAB9A 3596/4885MAOA 2379/4885MAOB 2795/4885 |
| US-20210002649-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | PDCD1, PDCD1LG2, CD274 | RAB9A 2800/4885MAOA 3936/4885MAOB 4161/4885 |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | GPI, ERG28, MAN2A1 | RAB9A 3912/4885MAOA 940/4885MAOB 690/4885 |
| US-10357477-B2 | Anticancer compounds | RB1, MCL1, TP53 | RAB9A 375/4885MAOA 3068/4885MAOB 2096/4885 |
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | HSD11B1, HSD3B1, P4HA1 | RAB9A 2595/4885MAOA 1244/4885MAOB 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.